CAR-NK Cells for Hodgkin's Lymphoma

This trial tests a new treatment using special immune cells, called CAR-NK cells (a type of cell therapy), to combat certain relapsed or hard-to-treat blood cancers, including Hodgkin's lymphoma. The researchers aim to determine if these cells can safely and effectively target and destroy cancer cells in patients unresponsive to other treatments. Participants will receive chemotherapy followed by the CAR-NK cell treatment over two cycles. This trial may suit individuals with relapsed blood cancers who haven't succeeded with previous therapies. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the chance to be among the first to receive this innovative therapy.

The trial protocol does not specify if you must stop taking your current medications. However, you cannot participate if you have received any anti-cancer treatment within the last 2 weeks or are on certain immunosuppressive therapies. It's best to discuss your specific medications with the trial team.

Research has shown that a new treatment using specially engineered cells, called TGFBR2 KO CAR27/IL-15 NK cells, might be safe and well-tolerated for treating certain cancers. In earlier studies, researchers administered these cells to patients with recurrent or hard-to-treat cancers, such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and the results were promising regarding safety.

These studies primarily aimed to determine a safe dose and observe patient responses to the treatment. The results indicated that patients tolerated the treatment well without serious side effects. However, this treatment remains in the early testing stages, so researchers are focused on ensuring safety and determining the optimal dose.

Unlike the standard treatments for Hodgkin's Lymphoma, which often include chemotherapy and radiation, the TGFBR2 KO CAR27/IL-15 NK cells offer a novel approach by harnessing the body's immune system. This treatment uses genetically engineered Natural Killer (NK) cells that are designed to better recognize and destroy cancer cells. Researchers are excited because these modified NK cells are less likely to cause severe side effects and may improve targeting of cancer cells, potentially leading to more effective and safer treatment outcomes. The inclusion of IL-15, a cytokine, helps boost the activity and persistence of these NK cells, offering a promising new strategy against Hodgkin's Lymphoma.

Studies have shown that specially engineered NK cells, known as TGFBR2 KO CAR27/IL-15 NK cells, might effectively fight cancer. In this trial, participants will receive these modified NK cells after lymphodepleting chemotherapy with Fludarabine and Cyclophosphamide. These cells enhance the natural ability of NK cells to locate and destroy cancer cells, particularly those with the CD70 protein. Research suggests that blocking the molecule TGF-β, which can weaken immune responses, boosts NK cell activity against cancer. Early results indicate that these modified NK cells can be safe and may help treat certain types of cancers that have returned or are resistant to treatment. Although still under study, the treatment shows promise in targeting and killing cancer cells.¹²⁶⁷⁸